Clinical Trial Update: 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa [Phase 2]

View source ↗

Summary

Phase 2, double-blind, placebo-controlled study evaluating the efficacy of 40 mg/day KW-6002 (istradefylline) added to levodopa/carbidopa in Parkinson's disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• istradefylline (KW-6002) (istradefylline)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED